Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A [0.03%]
不仅仅是革命：新型延长半衰期的第八因子替代品及非替代剂改变了A型血友病的治疗前景
Hussien Ahmed H Abdelgawad,Rachel Foster,Mario Otto
Hussien Ahmed H Abdelgawad
Hemophilia A, an X-linked genetic disorder, is characterized by a deficiency or dysfunction of clotting Factor VIII. The treatment landscape has substantially changed by introducing novel extended half-life factor VIII (EHL-FVIII) replaceme...
Sarah E Clarke,Kathryn A Fuller,Wendy N Erber
Sarah E Clarke
Multiple myeloma is a plasma cell neoplasm driven by primary (e.g. hyperdiploidy; IGH translocations) and secondary (e.g. 1q21 gains/amplifications; del(17p); MYC translocations) chromosomal events. These are important to detect as they inf...
Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management [0.03%]
与免疫缺陷/失调相关淋巴增生性疾病。修订分类和处理方法
Antonino Carbone,Amy Chadburn,Annunziata Gloghini et al.
Antonino Carbone et al.
Significant advances in the field of lymphoma have resulted in two recent classification proposals, the International Consensus Classification (ICC) and the 5th edition WHO. A few entities are categorized differently in the ICC compared to ...
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies [0.03%]
心碎剂：血液系统恶性肿瘤中心肌毒性的检测与预防
Azin Vakilpour,Bénédicte Lefebvre,Catherine Lai et al.
Azin Vakilpour et al.
Cancer survivors are at significant risk of cardiovascular (CV) morbidity and mortality; patients with hematologic malignancies have a higher rate of death due to heart failure compared to all other cancer subtypes. The majority of conventi...
Khaled M Musallam,M Domenica Cappellini,Thomas D Coates et al.
Khaled M Musallam et al.
α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and thus varying degrees of ineffective erythropoiesis, decreased red blood cell (RBC) s...
A Barrett,N Appleby,H Dreau et al.
A Barrett et al.
Richter transformation (RT) represents an aggressive histological transformation from chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug developm...
Gunjan Shah,Sergio Giralt,Parastoo Dahi
Gunjan Shah
Melphalan, has been a major component of myeloma therapy since the 1950s. In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to its potent anti-myeloma effe...
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances [0.03%]
原发性多中心卡斯特利曼病：诊断和治疗进展更新
Evan Lang,Frits van Rhee
Evan Lang
Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortal...
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease [0.03%]
个性化器官特异性慢性激素难治性移植物抗宿主病治疗方案
Hanaa Fatoum,Robert Zeiser,Shahrukh K Hashmi
Hanaa Fatoum
Chronic graft-versus-host-disease (cGvHD) remains the leading cause of morbidity among transplant recipients. The efficacy of second-line treatments varies widely based on many factors, including wide differences in the organ overall respon...
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape [0.03%]
阵发性夜间血红蛋白尿患者体验和治疗现状综述
Anem Waheed,Jamile Shammo,David Dingli
Anem Waheed
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by complement-mediated hemolysis and thrombosis through the alternative pathway. The most common symptom of PNH is fatigue due to chronic anemia, which can negatively impac...